Malignant melanoma
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Study selection Eligible articles will be English report on randomized controlled trials (RCTs). Inclusion of conference abstracts will be permissible for this analysis. The phase of the study will not serve as a criterion for exclusion. Patient selection Patient with cutaneous malignant melanoma will be the target population, without regard to the stage of cancer, histopathological type, or specific genetic mutation, provided these patients are identified as suitable for perioperative chemotherapy by the original study's authors. Treatment Concerned treatment is the perioperative ICI, including pre-operative (neo-adjuvant) and post-operative (adjuvant) therapies, regardless of the ICI type, drug dose, and regimens. Co-administration of cytotoxic agents and molecular targeted therapy will be acceptable.
Exclusion criteria
Exclusion criteria: Perioperative ICI combined with radiological treatment will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study-level outcomes of our concern will be the hazard ratios (HRs) of event-free survival (EFS, HRefs) and HR of OS (HRos). EFS includes PFS, DFS, and RFS. We will assess the Spearman's rank correlation between HRefs and HRos. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed